VERTEX PHARMACEUTICALS INCORPORATED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 401.7 USD | +0.15% |
|
+1.77% | -0.90% |
| 02:07pm | The market resurrects the Fed Put |  |
| 01:09pm | Futures Rise Pre-Bell Ahead of Latest Earnings Week; Asia Mostly Up, Europe Strong | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
01:31am
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
401.1
USD
Average target price
460.2
USD
Spread / Average Target
+14.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.90% | 104B | |
| +8.64% | 105B | |
| +5.44% | 22.94B | |
| -12.25% | 22.34B | |
| -6.31% | 19.25B | |
| -37.08% | 17.08B | |
| -8.69% | 16.96B | |
| +7.59% | 14.16B | |
| +38.96% | 12.63B | |
| +307.06% | 8.49B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Earnings Flash (VRTX) VERTEX PHARMACEUTICALS INCORPORATED Posts Q3 EPS $3.56, vs. Street Est of $3.05